|Description||This active molecular is a reversible FAAH (fatty acid amide hydrolase) inhibitor that increases levels of the neurotransmitter anandamide in the central nervous system and in peripheral tissues (except the brain and spinal cord) under the development of Bial-Portela & Ca. SA. BIA 10-2474 can interact with the human endocannabinoid system and was inpplicated in the treatment of a range of different medical conditions including anxiety, Parkinson's disease, chronic pain of multiple sclerosis, cancer, hypertension and obesity. Clinical trial with BIA 10-2474 was on-going. However, severe adverse events occurred in January 2016 affecting 5 patients, including leading to the death of one.|
|Synonyms||N-cyclohexyl-N-methyl-4-(1-oxidopyridin-1-ium-3-yl)imidazole-1-carboxamide;UNII-5AP1ZW859M; SCHEMBL427970; 5AP1ZW859M; GTPL9001; DOWVMJFBDGWVML-UHFFFAOYSA-N;|
|Solubility||Soluble in DMSO|
|Application||Neurological disorders; Pain; Psychiatric disorders|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator:Bial-Portela & Ca. SA.|
JNJ-40355003 is a selective fatty acid amide hydrolase (FAAH) inhibitor. JNJ-40355003 can elevate the plasma levels of anandamide, oleoyl ethanolamide, and palm...
LY2183240 is a novel and highly potent blocker of anandamide uptake. It inhibits fatty acid amide hydrolase (FAAH) activity. It increases brain anandamide conce...
JZL195 is a potent dual inhibitor of Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), enzymes that degrade the endocannabinoids 2-arachidon...
A metabolite of Gefitinib.
PF-04457845 is a potent and exquisitely selective inhibitor of FAAH, with an IC50 of 7.2 nM, and both analgesic and antiinflammatory effects in animal studies c...
Biochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of ...
OL135 is a CNS penetrant, highly potent and selective reversible inhibitor of FAAH. It exhibits analgesic pharmacology in various animal models without the moto...
This active molecular is a reversible FAAH (fatty acid amide hydrolase) inhibitor that increases levels of the neurotransmitter anandamide in the central nervou...
JNJ-42165279 is a fatty acid amide hydrolase (FAAH) inhibitor developed by Janssen Pharmaceutica and IC50 value is 70 nM. It is described as a covalently bindin...
URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.
PF-3845 is a potent, selective, and irreversible inhibitor of FAAH (Ki = 0.23 μM). It reduces inflammatory pain via a cannabinoid receptor-dependent mechanism.
FAAH inhibitor 1
Time-dependent preincubation study of FAAH inhibitor 1 was consistent with it being a reversible inhibitor. Activity-based protein-profiling (ABPP) evaluation o...